Modafinil Glenmark

Modafinil, the active ingredient in Modafinil Glenmark, is a eugeroic (wakefulness‑promoting agent) presented as an oral dosage form for oral use. It is indicated for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift‑work disorder. GNH USA supplies Modafinil Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil acts on central nervous system pathways that regulate wakefulness, providing benefit in several sleep‑related disorders. - Narcolepsy: reduces excessive daytime sleepiness in patients with narcolepsy. - Obstructive sleep apnea: improves wakefulness in patients whose sleep apnea is treated with CPAP or other therapies. - Shift‑work disorder: helps maintain alertness in individuals working non‑traditional hours.

Modafinil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: feelings of nervousness or tension. - Dry mouth: reduced salivation. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe rash or Stevens‑Johnson syndrome: requires immediate medical attention. - Psychiatric disturbances: emergence of mania, depression, or hallucinations. - Cardiovascular events: chest pain, arrhythmia, or hypertension. - Hypersensitivity reactions: swelling, difficulty breathing, or anaphylaxis.

Before initiating therapy, consider the following safety measures. - Assess cardiovascular status: evaluate blood pressure and heart disease history. - Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. - Monitor psychiatric symptoms: watch for anxiety, depression, or mania. - Adjust dose in hepatic impairment: consider lower dosing in patients with liver dysfunction. - Store at ambient temperature: keep in original container, protect from moisture and light.

Modafinil can affect the metabolism of several co‑administered drugs.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations of modafinil. - Anticonvulsants (e.g., carbamazepine): may reduce modafinil efficacy. - Oral contraceptives: may lower hormonal contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may blunt wake‑promoting effect. - Antidepressants (e.g., SSRIs): may increase risk of anxiety or insomnia. - Alcohol: may enhance side‑effect profile such as dizziness or headache.